Surgery for stage IIB–IIIB small cell lung cancer

World Journal of Surgical Oncology

Research

Suyu Wang¹  Zhida Huang²  Yue Liu²  Kaixing Ai³  Peng Zhang⁴ 

[1] Department of Thoracic Surgery, School of Medicine, Shanghai Pulmonary Hospital, Tongji University, 507 Zhengmin Road, 200433, Shanghai, China;The Second Affiliated Hospital of Nanchang University, Medical Graduate School, Nanchang University, Nanchang, China;The Second Affiliated Hospital of Nanchang University, Medical Graduate School, Nanchang University, Nanchang, China;Department of General Surgery, School of Medicine, Shanghai Pulmonary Hospital, Tongji University, 507 Zhengmin Road, 200433, Shanghai, China;The Second Affiliated Hospital of Nanchang University, Medical Graduate School, Nanchang University, Nanchang, China;Department of Thoracic Surgery, School of Medicine, Shanghai Pulmonary Hospital, Tongji University, 507 Zhengmin Road, 200433, Shanghai, China;

关键词: Sublobectomy;    Lobectomy;    Pneumonectomy;    Small cell lung cancer;    SEER;   

DOI  :  10.1186/s12957-023-03196-2

 received in 2023-08-02, accepted in 2023-09-19,  发布年份 2023

来源: Springer

【 摘 要 】

PurposeThe NCCN guidelines do not recommend surgery for T3–4N0M0/T1–4N1–2M0 small cell lung cancer (SCLC) due to a lack of evidence.MethodsData of patients with T3–4N0M0/T1–4N1–2M0 SCLC were extracted from the Surveillance, Epidemiology, and End Results (SEER) database to determine the impact of surgery on this population. The Kaplan–Meier method, univariable and multivariable Cox proportional hazard regression, and propensity score matching (PSM) were used to compare the overall survival (OS) between the surgery and non-surgery groups. In addition, we explored whether sublobectomy, lobectomy, and pneumonectomy could provide survival benefits.ResultsIn total, 8572 patients with SCLC treated without surgery and 342 patients treated with surgery were included in this study. The PSM-adjusted hazard ratio (HR, 95% CI) for surgery vs. no surgery, sublobectomy vs. no surgery, lobectomy vs. no surgery, pneumonectomy vs. no surgery, and lobectomy plus adjuvant chemoradiotherapy vs. chemoradiotherapy were 0.71 (0.61–0.82) (P < 0.001), 0.91 (0.70–1.19) (P = 0.488), 0.60 (0.50–0.73) (P < 0.001), 0.57 (0.28–1.16) (P = 0.124), and 0.73 (0.56–0.96) (P = 0.023), respectively. The subgroup analysis demonstrated consistent results.ConclusionsLobectomy improved OS in patients with T3–4N0M0/T1–4N1–2M0 SCLC, while pneumonectomy also demonstrated a tendency to improve OS without statistical significance; however, sublobectomy showed no survival benefit.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 9

Fig. 9

Fig. 2

Fig. 1

12888_2023_5299_Article_IEq1.gif